NASDAQ:CNAT - Conatus Pharmaceuticals News Headlines Sign in or create an account to add this stock to your watchlist. Get Started $1.52 0.00 (0.00 %) (As of 12/16/2018 09:39 AM ET)Previous Close$1.52Today's Range$1.50 - $1.5952-Week Range$1.49 - $7.95Volume878,143 shsAverage Volume1.08 million shsMarket Capitalization$46 millionP/E Ratio-2.49Dividend YieldN/ABeta1.99 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Headlines Conatus Pharmaceuticals (NASDAQ CNAT) News Headlines Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance DateHeadlineConatus: Was That Trial A Total Failure?seekingalpha.com - December 11 at 4:46 PMConatus: A Rare Investment For Opportunistic Investorsseekingalpha.com - December 11 at 4:46 PMConatus And Emricasan In NASH Cirrhotic Portal Hypertension: The Overlooked Therapeutic Promiseseekingalpha.com - December 10 at 9:52 AMOppenheimer Research Analysts Cut Earnings Estimates for Conatus Pharmaceuticals Inc (CNAT)www.americanbankingnews.com - December 10 at 1:44 AMFY2019 Earnings Estimate for Conatus Pharmaceuticals Inc (CNAT) Issued By SunTrust Bankswww.americanbankingnews.com - December 10 at 1:44 AMShares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpoint - MarketWatchwww.marketwatch.com - December 8 at 9:16 AMConatus Pharmaceuticals (CNAT) PT Lowered to $10 at Oppenheimerwww.streetinsider.com - December 7 at 9:08 AMWhy Conatus Pharma Shares Were Halved247wallst.com - December 7 at 9:08 AMConatus' Emricasan Misses Primary Endpoint in Mid-Stage Studyfinance.yahoo.com - December 7 at 9:08 AMConatus Pharmaceuticals (CNAT) PT Lowered to $14 at H.C. Wainwrightwww.streetinsider.com - December 7 at 9:08 AMImplied Volatility Surging for Conatus (CNAT) Stock Optionswww.zacks.com - December 7 at 9:08 AMConatus May Still Have A Path Forward After Latest Phase 2b Dataseekingalpha.com - December 7 at 9:08 AMU.S. STOCKS ON THE MOVE-Chipmakers, oil stocks, Facebook, industrial stocks - Nasdaqwww.nasdaq.com - December 6 at 4:45 PMU.S. STOCKS ON THE MOVE-Apple, chipmakers, oil stocks, Boeing, Amazon, Conatus - Nasdaqwww.nasdaq.com - December 6 at 4:45 PMConatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis - GlobeNewswireglobenewswire.com - December 6 at 4:45 PMU.S. STOCKS ON THE MOVE-Oil stocks, Facebook, Marvell Technology, Conatus Pharma - Nasdaqwww.nasdaq.com - December 6 at 4:45 PMShares of Conatus Pharmaceuticals plummet over 50% after Phase 2 trial fails to meet primary endpointfinance.yahoo.com - December 6 at 4:45 PMConatus Pharmaceuticals (CNAT) PT Lowered to $12.00 at SunTrust Bankswww.americanbankingnews.com - December 6 at 1:29 PMConatus Pharmaceuticals (CNAT) Cut to Hold at Stifel Nicolauswww.americanbankingnews.com - December 6 at 1:01 PMConatus Pharma's emricasan flunks mid-stage NASH study; shares down 62% premarketseekingalpha.com - December 6 at 9:08 AMConatus (CNAT) ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosis Did Dot Meet Primary Endpointwww.streetinsider.com - December 6 at 9:08 AMToday's Research Reports on Trending Tickers: Conatus Pharmaceuticals and Exelixisfinance.yahoo.com - December 6 at 9:08 AMConatus Pharmaceuticals (CNAT) Given a $10.00 Price Target at Oppenheimerwww.americanbankingnews.com - December 6 at 8:09 AMConatus Announces Results from ENCORE-PH Phase 2b Clinical Trial in NASH Cirrhosisfinance.yahoo.com - December 5 at 9:28 AMWhy Is Conatus (CNAT) Up 4.7% Since Last Earnings Report?www.zacks.com - December 3 at 9:36 AMConatus Pharmaceuticals Inc (CNAT) Given Consensus Recommendation of "Buy" by Brokerageswww.americanbankingnews.com - November 30 at 9:54 AM Brokerages Expect Conatus Pharmaceuticals Inc (CNAT) Will Post Quarterly Sales of $8.51 Millionwww.americanbankingnews.com - November 29 at 5:49 AM-$0.14 EPS Expected for Conatus Pharmaceuticals Inc (CNAT) This Quarterwww.americanbankingnews.com - November 27 at 5:18 AMWhen Will Conatus Pharmaceuticals Inc (NASDAQ:CNAT) Become Profitable?finance.yahoo.com - November 16 at 4:39 PMDo Options Traders Know Something About Conatus (CNAT) Stock We Don't?finance.yahoo.com - November 14 at 4:40 PMDo Options Traders Know Something About Conatus (CNAT) Stock We Don't?www.zacks.com - November 14 at 8:52 AMConatus Pharmaceuticals Announces Presentations and Posters at AASLD Annual Meetingfinance.yahoo.com - November 8 at 9:24 AMConatus Pharmaceuticals among healthcare gainers; Clearside Biomedical leads the losersseekingalpha.com - November 7 at 9:18 AMConatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimatesfinance.yahoo.com - November 2 at 4:43 PMEdited Transcript of CNAT earnings conference call or presentation 1-Nov-18 8:30pm GMTfinance.yahoo.com - November 2 at 4:43 PMConatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimatesfinance.yahoo.com - November 2 at 4:43 PMConatus Pharma Q3 revenues down 20%seekingalpha.com - November 2 at 9:57 AMConatus Pharmaceuticals (CNAT) CEO Steve Mento on Q3 2018 Results - Earnings Call Transcriptseekingalpha.com - November 2 at 9:57 AMConatus: 3Q Earnings Snapshotfinance.yahoo.com - November 2 at 9:57 AMConatus Pharmaceuticals (CNAT) Reports Q3 Loss, Misses Revenue Estimatesfinance.yahoo.com - November 2 at 9:57 AMConatus Pharmaceuticals EPS in-line, misses on revenueseekingalpha.com - November 1 at 4:44 PMConatus Pharmaceuticals Reports Third Quarter 2018 Financial Results and Program Updatesfinance.yahoo.com - November 1 at 4:44 PMConatus Pharmaceuticals to Report Third Quarter 2018 Financial Resultsfinance.yahoo.com - October 25 at 9:10 AMConatus Pharmaceuticals: Emricasan And Severe Portal Hypertensionseekingalpha.com - October 24 at 4:36 PMConatus And Emricasan: The Momentseekingalpha.com - October 8 at 4:39 PMConatus Pharmaceuticals (CNAT) Announces Three Accepted Abstracts for AASLDwww.streetinsider.com - October 3 at 4:37 PMConatus Pharmaceuticals Announces Three Accepted Abstracts for AASLD Annual Meetingfinance.yahoo.com - October 2 at 4:37 PMConatus Pharmaceuticals, Upcoming Presentations, Analysts Review and Targetfinance.yahoo.com - September 25 at 8:45 AMExpected Value Investing: Diving Deeper On Conatusseekingalpha.com - September 24 at 4:39 PMConatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertensionfeeds.benzinga.com - September 20 at 7:52 AM This page was last updated on 12/16/2018 by MarketBeat.com StaffFeatured Article: How does a 12b-1 fee affect fund performance?